SmallCapInvestor has an article on Emergent BioSolutions and gives the stock a $15 price target (registration required to view the entire article). The author does not provide a financial analysis on the company, but talks about the company's anthrax vaccine (BioThrax) and other products that are in Stage II trials such as their typhoid vaccine candidate and hepatitis B vaccine candidate.
Disclosure: I own shares of Emergent? Why? They are a profitable company that sells the only FDA approved anthrax vaccine to the government. They are using those profits to develop other potential blockbuster vaccines. Click here to see my previous coverage of Emergent.